Monte Rosa Therapeutic (GLUE) Q4 2024 earnings summary

Executive summary

• Reported Q4 and full year 2024 results, highlighting clinical and preclinical progress in immunology, inflammation, and oncology pipelines, with a focus on molecular glue degraders (MGDs) and strategic emphasis on castration-resistant prostate cancer (CRPC) for MRT-2359.

• Advanced MRT-6160 (VAV1 program) with positive Phase 1 data showing >90% VAV1 degradation, strong cytokine and T/B cell inhibition, and favorable safety, supporting Phase 2 development and a global partnership with Novartis.

• NEK7 degrader MRT-8102 demonstrated potent, selective degradation and robust preclinical efficacy, with IND submission planned for H1 2025; CNS-optimized NEK7 program IND planned for 2026.

• Oncology focus shifted to CRPC for MRT-2359 based on early efficacy (1 PR, 2 SD in initial patients), deprioritizing lung and neuroendocrine tumor cohorts due to low biomarker positivity.

• CCNE1 and CDK2 MGDs showed strong preclinical tumor regression and synergy with CDK4/6 inhibitors, with IND submissions targeted for 2026.

Financial highlights

• Received $150M upfront from Novartis for global license of MRT-6160, with up to $2.1B in milestones and US profit/loss share plus ex-US royalties.

• Cash, equivalents, and marketable securities at December 31, 2024: $377M, up from $247.1M at September 30, 2024; cash runway anticipated into 2028.

• Q4 2024 collaboration revenue: $60.6M; full year 2024: $75.6M, reflecting new Novartis and Roche agreements.

• Q4 2024 net income: $13.4M (vs. $33.3M net loss in Q4 2023); full year 2024 net loss: $72.7M (improved from $135.4M loss in 2023).

Outlook and guidance

• Phase 2 studies for MRT-6160 are being prepared in collaboration with Novartis; timing to be determined.

• IND submission for MRT-8102 expected in H1 2025; CNS-optimized NEK7 and CDK2/Cyclin E1 MGDs INDs planned for 2026.

• Additional clinical data for MRT-2359 in CRPC and hormone receptor-positive breast cancer expected in H2 2025.